EA201691793A1 - Способ получения состава на основе вилдаглиптина в атмосфере инертного газа - Google Patents

Способ получения состава на основе вилдаглиптина в атмосфере инертного газа

Info

Publication number
EA201691793A1
EA201691793A1 EA201691793A EA201691793A EA201691793A1 EA 201691793 A1 EA201691793 A1 EA 201691793A1 EA 201691793 A EA201691793 A EA 201691793A EA 201691793 A EA201691793 A EA 201691793A EA 201691793 A1 EA201691793 A1 EA 201691793A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inert gas
gas atmosphere
vildagliptina
obtaining
composition based
Prior art date
Application number
EA201691793A
Other languages
English (en)
Inventor
Али Тюркильмаз
Гюлай Елькен
Мехтап Сайдам
Онур Ульген
Original Assignee
Сановель Илач Санайи Ве Тиджарет А.Ш.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TR2014/02685A external-priority patent/TR201402685A1/tr
Application filed by Сановель Илач Санайи Ве Тиджарет А.Ш. filed Critical Сановель Илач Санайи Ве Тиджарет А.Ш.
Publication of EA201691793A1 publication Critical patent/EA201691793A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к способу получения фармацевтической композиции на основе вилдаглиптина в атмосфере инертного газа, не содержащей кислорода. Настоящее изобретение, в частности, относится к фармацевтической композиции на основе вилдаглиптина, полученной посредством данного способа, которая является физиологически и химически стабильной при воздействии кислорода.
EA201691793A 2014-03-06 2015-03-05 Способ получения состава на основе вилдаглиптина в атмосфере инертного газа EA201691793A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
TR2014/02685A TR201402685A1 (tr) 2014-03-06 2014-03-06 Vildagliptinin farmasotik formulasyonları.
TR201412836 2014-11-03
PCT/EP2015/054666 WO2015132359A1 (en) 2014-03-06 2015-03-05 Vildagliptin formulation process under inert gas atmosphere

Publications (1)

Publication Number Publication Date
EA201691793A1 true EA201691793A1 (ru) 2016-12-30

Family

ID=52726949

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691793A EA201691793A1 (ru) 2014-03-06 2015-03-05 Способ получения состава на основе вилдаглиптина в атмосфере инертного газа

Country Status (4)

Country Link
US (1) US20170014380A1 (ru)
EP (1) EP2915528A1 (ru)
EA (1) EA201691793A1 (ru)
WO (1) WO2015132359A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR202010700A2 (tr) * 2020-07-06 2022-01-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vi̇ldagli̇pti̇n ve en az bi̇r farmasöti̇k olarak kabul edi̇lebi̇li̇r eksi̇pi̇yan i̇çeren bi̇r formülasyon
CN112957355A (zh) * 2021-04-07 2021-06-15 烟台万润药业有限公司 一种维格列汀片剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
JP4939217B2 (ja) * 2003-08-06 2012-05-23 グリューネンタ−ル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 乱用防止剤形
PL3738585T3 (pl) 2004-01-20 2023-04-17 Novartis Ag Preparat i sposób jego bezpośredniego prasowania
GT200600008A (es) 2005-01-18 2006-08-09 Formulacion de compresion directa y proceso
MY152185A (en) 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
EP2578208B1 (en) * 2011-10-06 2014-05-21 Sanovel Ilac Sanayi ve Ticaret A.S. DPP-IV inhibitor solid dosage formulations
US10996236B2 (en) * 2014-07-22 2021-05-04 Fisher Controls International Llc Control device position feedback with accelerometer

Also Published As

Publication number Publication date
EP2915528A1 (en) 2015-09-09
US20170014380A1 (en) 2017-01-19
WO2015132359A1 (en) 2015-09-11

Similar Documents

Publication Publication Date Title
GEP20207182B (en) Cyclic di-nucleotide compounds as sting agonists
EA201790630A1 (ru) Способы получения рибозидов
EA202092987A2 (ru) Липид, содержащий докозапентаеновую кислоту
EP4282983A3 (en) Compositions and methods for polynucleotide sequencing
MX2017008136A (es) Sal de l-tartrato de pridopidina.
CY1124587T1 (el) Μεθοδος για την παρασκευη toy brivaracetam
BR112017012210A2 (pt) solução conservante de célula, uso da mesma e método de produção de solução conservante de célula
EA202091397A1 (ru) Бензохинолоновые ингибиторы vmat2
TW201612319A (en) Microorganism producing O-phosphoserine and a method for producing O-phosphoserine or L-cysteine using the same
EA201691649A1 (ru) Способ получения противогрибковых соединений
CY1120759T1 (el) Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης
EA201591712A1 (ru) Антибиотические композиции на основе цефтолозана
EA201691648A1 (ru) Способ получения противогрибковых соединений
PH12016502002B1 (en) Novel bacteriophage and composition comprising same
MX2018003678A (es) Metodos moleculares de aseguramiento de la calidad para su uso en la secuenciacion.
MX2017005578A (es) Métodos de administración de composiciones de amantadina.
EA201690793A1 (ru) Способ получения лиофилизированной фармацевтической композиции, содержащей митомицин c
TW201613953A (en) Process for the preparation of cyclic depsipeptides
EA201890177A1 (ru) Мультиспецифические связывающие белки
CY1124569T1 (el) Φαρμακοτεχνικη μορφη που περιεχει γλυκοπυρρολικο, μεθοδος και συσκευη
MX2023009432A (es) Metodo para crear un compuesto a base de mercurio, compuesto a base de mercurio, metodos de uso del compuesto a base de mercurio y usos del compuesto a base de mercurio.
EA201992168A1 (ru) Аналоги деутетрабеназина, их получение и применение
EA201691793A1 (ru) Способ получения состава на основе вилдаглиптина в атмосфере инертного газа
EA201890818A1 (ru) Режим комбинированной терапии для лечения hcv
BR112018003714A8 (pt) Composições de ácido de peso aumentado que compreendem aminoácidos